{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:04:06Z","timestamp":1780506246454,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.oret.2017.08.015","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T05:30:14Z","timestamp":1509946214000},"page":"441-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Treatment of Geographic Atrophy with Intravitreal Sirolimus"],"prefix":"10.1016","volume":"2","author":[{"given":"Gary","family":"Gensler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci E.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitha","family":"Domalpally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"Danis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Blodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Jack","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hoskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Baker","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Elman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E.","family":"Fish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Margherio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2017.08.015_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2017.08.015_bib2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.ophtha.2007.08.030","article-title":"Retinal precursors and the development of geographic atrophy in age-related macular degeneration","volume":"115","author":"Klein","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2017.08.015_bib3","first-page":"465","article-title":"Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2017.08.015_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1350-9462(00)00025-2","article-title":"Immunological and aetiological aspects of macular degeneration","volume":"20","author":"Penfold","year":"2001","journal-title":"Prog Retina Eye Res"},{"key":"10.1016\/j.oret.2017.08.015_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev-genom-090413-025610","article-title":"Age-related macular degeneration: genetics and biology coming together","volume":"15","author":"Fritsche","year":"2014","journal-title":"Ann Rev Genomics Hum Genet"},{"key":"10.1016\/j.oret.2017.08.015_bib6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nri3459","article-title":"Immunology of age-related macular degeneration","volume":"13","author":"Ambati","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.oret.2017.08.015_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.oret.2017.08.015_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.oret.2017.08.015_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","article-title":"Complement factor H polymorphism and age-related macular degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.oret.2017.08.015_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0014-4835(02)00332-9","article-title":"Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration","volume":"76","author":"Gupta","year":"2003","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.oret.2017.08.015_bib11","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/bjo.2009.165563","article-title":"Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration","volume":"94","author":"Cherepanoff","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2017.08.015_bib12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1006\/exer.2001.1094","article-title":"Complement activation and inflammatory processes in Drusen formation and age related macular degeneration","volume":"73","author":"Johnson","year":"2001","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.oret.2017.08.015_bib13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9394(02)01624-0","article-title":"A\u00a0role for local inflammation in the formation of drusen in the aging eye","volume":"134","author":"Anderson","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2017.08.015_bib14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1350-9462(01)00010-6","article-title":"An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration","volume":"20","author":"Hageman","year":"2001","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2017.08.015_bib15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/jop.2011.0226","article-title":"Tolerability and pharmacokinetics of intravitreal sirolimus","volume":"28","author":"Mudumba","year":"2012","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.oret.2017.08.015_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"10.1016\/j.oret.2017.08.015_bib17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.oret.2017.08.015_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI44303","article-title":"mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice","volume":"121","author":"Zhao","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"3 Suppl","key":"10.1016\/j.oret.2017.08.015_bib19","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1016\/S0041-1345(03)00356-7","article-title":"The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation","volume":"35","author":"Camardo","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.oret.2017.08.015_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ajhp\/61.5.449","article-title":"Sirolimus-eluting coronary stent","volume":"61","author":"Vishnevetsky","year":"2004","journal-title":"Am J Health Sys Pharm"},{"key":"10.1016\/j.oret.2017.08.015_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ophtha.2011.07.034","article-title":"A\u00a0randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema","volume":"119","author":"Dugel","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2017.08.015_bib22","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1167\/iovs.13-11650","article-title":"Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I\/II clinical trial","volume":"54","author":"Wong","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2017.08.015_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1167\/iovs.14-15877","article-title":"Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I\/II clinical trial","volume":"56","author":"Petrou","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2017.08.015_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12348-010-0015-5","article-title":"A\u00a0retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis","volume":"1","author":"Phillips","year":"2011","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.oret.2017.08.015_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1869-5760-3-32","article-title":"Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study","volume":"3","author":"Nguyen","year":"2013","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.oret.2017.08.015_bib26","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2013.4997","article-title":"Lutein\u00a0+ zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial","volume":"309","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2017.08.015_bib27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/IAE.0000000000000801","article-title":"Noninfectious vitreitis after intravitreal injection of anti-VEGF agents: variations in rates and presentation by medication","volume":"36","author":"Williams","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2017.08.015_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajo.2016.02.028","article-title":"Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept","volume":"165","author":"Rayess","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2017.08.015_bib29","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.ophtha.2015.07.005","article-title":"The association between intravitreal steroids and post-injection endophthalmitis rates","volume":"122","author":"VanderBeek","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2017.08.015_bib30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3928\/23258160-20150610-08","article-title":"Current infectious endophthalmitis rates after intravitreal injections of anti-vascular endothelial growth factor agents and outcomes of treatment","volume":"46","author":"Gregori","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2017.08.015_bib31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ophtha.2014.10.027","article-title":"Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT)","volume":"122","author":"Meredith","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2017.08.015_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A\u00a0large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653017302944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653017302944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:24:00Z","timestamp":1762853040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653017302944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S2468653017302944"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2017.08.015","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Geographic Atrophy with Intravitreal Sirolimus","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2017.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}